SOLENO THERAPEUTICS INC
已退市CIK 1484565fmd_01WBX1CPNDCMCNDD0ERXYAJJ3R制造业 · 医药制剂模板: 标准
覆盖范围: 2013年1月01日 至 2026年3月31日，共 51 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 1 | – | – | – | – | – | – | – | – | – |
| 营业成本 | 2 | – | – | – | – | – | – | – | – | 3 |
| 毛利润 | (0) | – | – | – | – | – | – | – | – | – |
| 研发费用 | 2 | 3 | 7 | 16 | 23 | 21 | 15 | 25 | 79 | 41 |
| 销售、一般及管理费用 | 6 | 7 | – | – | – | – | – | 13 | 106 | 132 |
| 营业费用合计 | 8 | 12 | 14 | 23 | 36 | 32 | 24 | 41 | 188 | 181 |
| 营业利润 | (8) | (12) | (14) | (23) | (36) | (32) | (24) | (41) | (188) | 9 |
| 利息费用 | – | – | – | – | – | – | 0 | 0 | 0 | 5 |
| 利息及投资收益 | – | – | – | – | – | – | 0 | 3 | 12 | 17 |
| 其他营业外收入（支出） | 2 | (1) | 2 | (7) | 12 | 1 | 0 | 2 | 12 | 11 |
| 税前利润 | (7) | (13) | (12) | (31) | (25) | (31) | (24) | (39) | (176) | 21 |
| 所得税费用 | 0 | (2) | 0 | – | – | – | – | 0 | 0 | 0 |
| 持续经营净利润 | (7) | (12) | (12) | (31) | – | – | – | (39) | (176) | 21 |
| 净利润 | (12) | (15) | (13) | (31) | (25) | (31) | (24) | (39) | (176) | 21 |
| 归属于普通股股东的净利润 | (16) | (16) | – | – | – | – | – | (39) | (176) | 20 |